MX2018001751A - Dihidroquinolinonas aril-sustituidas, su preparacion y su uso como farmaceuticos. - Google Patents

Dihidroquinolinonas aril-sustituidas, su preparacion y su uso como farmaceuticos.

Info

Publication number
MX2018001751A
MX2018001751A MX2018001751A MX2018001751A MX2018001751A MX 2018001751 A MX2018001751 A MX 2018001751A MX 2018001751 A MX2018001751 A MX 2018001751A MX 2018001751 A MX2018001751 A MX 2018001751A MX 2018001751 A MX2018001751 A MX 2018001751A
Authority
MX
Mexico
Prior art keywords
dihydroquinolinones
aryl
substituted
pharmaceuticals
preparation
Prior art date
Application number
MX2018001751A
Other languages
English (en)
Inventor
Johnstone Shawn
Jacquemot Guillaume
Bayrakdarian Malken
S Albert Jeffrey
Griffin Andrew
Original Assignee
Neomed Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neomed Inst filed Critical Neomed Inst
Publication of MX2018001751A publication Critical patent/MX2018001751A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta solicitud se relaciona con dihidroquinolinonas aril-sustituidas de la fórmula (I), composiciones que los comprenden y sus usos en el tratamiento de enfermedades y condiciones en la que se indica la inhibición de una bromodomaina. Por ejemplo, la solicitud se relaciona con dihidroquinolinonas aril-sustituidas y a su uso como inhibidores de bromodomaina. La presente solicitud también se relaciona con el tratamiento o prevención de trastornos proliferativos, trastornos auto-inmunes, trastornos inflamatorios, trastornos dérmicos, y neoplasmas, incluyendo tumores y/o cánceres.
MX2018001751A 2015-08-11 2016-08-11 Dihidroquinolinonas aril-sustituidas, su preparacion y su uso como farmaceuticos. MX2018001751A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562203623P 2015-08-11 2015-08-11
US201662356579P 2016-06-30 2016-06-30
PCT/CA2016/050943 WO2017024408A1 (en) 2015-08-11 2016-08-11 Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
MX2018001751A true MX2018001751A (es) 2018-08-01

Family

ID=57982883

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001751A MX2018001751A (es) 2015-08-11 2016-08-11 Dihidroquinolinonas aril-sustituidas, su preparacion y su uso como farmaceuticos.

Country Status (11)

Country Link
US (2) US10501438B2 (es)
EP (1) EP3334717B1 (es)
JP (1) JP2018527340A (es)
KR (1) KR20180039117A (es)
CN (1) CN108290856A (es)
AU (1) AU2016305513A1 (es)
CA (1) CA2994472A1 (es)
HK (1) HK1256753A1 (es)
IL (1) IL257347A (es)
MX (1) MX2018001751A (es)
WO (1) WO2017024408A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020093162A1 (en) * 2018-11-07 2020-05-14 Neomed Institute Treatment of bet inhibitor-resistant cancers and other diseases responsive to dual bet and cbp/ep300 inhibition therapy
BR112021017831A2 (pt) * 2019-03-11 2021-11-30 Collaborative Medicinal Dev Llc Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
CN112239456B (zh) * 2020-06-09 2021-09-07 浙江理工大学 一种取代2，3-二氢喹诺酮化合物的制备方法
CN114276333B (zh) * 2020-09-28 2023-05-09 中国科学院上海药物研究所 二氢喹喔啉类溴结构域二价抑制剂
CN118005653A (zh) * 2023-04-23 2024-05-10 信义核新(北京)生物科技有限公司 喹诺酮类似物及其用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550166A (en) 1984-05-21 1985-10-29 American Cyanamid Company (Pyridinyl)-1,2,4-triazolo[4,3-a]pyridines
US4785005A (en) * 1986-06-25 1988-11-15 Rorer Pharmaceutical Corporation 6-(6-alkylpyridone)-carbostyril compounds and their cardiotonic uses
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE4237656A1 (de) 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AU760020B2 (en) 1998-08-31 2003-05-08 Merck & Co., Inc. Novel angiogenesis inhibitors
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
RU2006121487A (ru) 2003-12-18 2007-12-27 Пфайзер Продактс Инк. (Us) СПОСОБЫ ЛЕЧЕНИЯ ОСТРОГО ВОСПАЛЕНИЯ У ЖИВОТНЫХ С ПОМОЩЬЮ ИНГИБИТОРОВ р38 МАР-киназы
WO2005089763A1 (en) 2004-03-19 2005-09-29 Warner-Lambert Company Llc Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2009050183A2 (en) 2007-10-17 2009-04-23 Novartis Ag Imidazo [1, 2-a] pyridine derivatives useful as alk inhibitors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011060235A1 (en) 2009-11-16 2011-05-19 Schering Corporation Imidazole derivatives and methods of use thereof
PL2651939T3 (pl) 2010-12-13 2015-10-30 Array Biopharma Inc Podstawione związki N-(1H-indazol-4-ylo)imidazo[1,2-a]pirydyno-3-karboksyamidu jako inhibitory receptorowych kinaz tyrozynowych typu III
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
JP6215315B2 (ja) 2012-06-12 2017-10-18 アッヴィ・インコーポレイテッド ピリジノンおよびピリダジノン誘導体
KR102092988B1 (ko) 2012-09-28 2020-03-25 벤더르빌트 유니버시티 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들
US20140094456A1 (en) 2012-10-02 2014-04-03 Intermune, Inc. Anti-fibrotic pyridinones
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014095774A1 (de) 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydropyridopyrazinone
EP2935253B1 (en) * 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
WO2014128655A1 (en) 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
EP2968360B1 (en) 2013-03-14 2021-01-20 ConverGene LLC Quinolinone derivatives for the inhibition of bromodomain-containing proteins
PT2970265T (pt) 2013-03-15 2018-10-23 Plexxikon Inc Compostos heterocíclicos e suas utilizações
WO2014152029A2 (en) 2013-03-15 2014-09-25 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
EP3010917B1 (en) 2013-06-21 2018-01-31 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
CN105518001A (zh) 2013-07-09 2016-04-20 拜耳制药股份公司 Bet蛋白抑制性的改性的二氢喹喔啉酮类化合物和二氢吡啶并吡嗪酮类化合物
US20150051208A1 (en) 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
WO2015049629A1 (en) 2013-10-01 2015-04-09 Piramal Enterprises Limited Imidazoquinoline compounds as bromodomain inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
MX2016007346A (es) 2013-12-09 2016-09-13 Abbvie Inc Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
KR102394518B1 (ko) 2014-01-09 2022-05-06 오리온 코포레이션 브로모도메인 억제제로서의 비사이클릭 헤테로사이클릭 유도체
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド 抗線維性ピリジノン
KR102430144B1 (ko) * 2014-04-23 2022-08-08 인사이트 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
US20190092761A1 (en) 2014-11-13 2019-03-28 Convergene Llc Methods and Compositions for Inhibition of Bromodomain and Extratermial Proteins
CA2966298A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CA2966452A1 (en) 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
GB201503720D0 (en) 2015-03-05 2015-04-22 Glaxosmithkline Ip No 2 Ltd Chemical compound
GB201504689D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors

Also Published As

Publication number Publication date
CA2994472A1 (en) 2017-02-16
EP3334717A1 (en) 2018-06-20
KR20180039117A (ko) 2018-04-17
US10501438B2 (en) 2019-12-10
IL257347A (en) 2018-03-29
JP2018527340A (ja) 2018-09-20
US20180230130A1 (en) 2018-08-16
US20200299262A1 (en) 2020-09-24
EP3334717A4 (en) 2019-02-13
EP3334717B1 (en) 2020-07-01
HK1256753A1 (zh) 2019-10-04
CN108290856A (zh) 2018-07-17
AU2016305513A1 (en) 2018-03-08
WO2017024408A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
MX2018001756A (es) Benzimidazoles sustituidos, su preparacion y su uso como productos farmaceuticos.
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
PH12016500024A1 (en) Bromodomain inhibitor
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
GEP20217247B (en) Indole derivatives for use in medicine
IN2014MN02069A (es)
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
NZ722326A (en) Tricyclic compounds as anticancer agents
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
MX2018001751A (es) Dihidroquinolinonas aril-sustituidas, su preparacion y su uso como farmaceuticos.
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX369952B (es) Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1.
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA031679B9 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
EA201791365A1 (ru) Замещенный пиридил-циклоалкил-карбоновые кислоты, содержащие их композиции и их медицинское применение